Stepping Out, Not Up: Better Returns for VCs Through M&A?

IPOs are no longer a liquidity event for venture investors, who are increasingly turning to M&A to help balance portfolio returns.

If there was any question about whether it's becoming more difficult for venture capitalists to cash in with an IPO, comparing the recent IPO window of 2003-04 with the previous window in 1999-2000 should settle most arguments on the subject. (See Exhibit 1.) This analysis even omits the nearly uniformly poor performances of 2005's biotech IPO class, which has been beset by IPO price slashing and poor aftermarket trading. (See "Bad Haircuts: 2005's Biotech IPOs—Getting Out at Any Price?" START-UP, March 2005 Also see "Bad Haircuts: 2005's Biotech IPOs--Getting Out at Any Price?" - Scrip, 1 March, 2005..)

What's more, in the recent past, compared to the 1995-96 and 1999-2000 windows, biotech companies are having to raise a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.